Elevation of CKP induced by ezetimibe in monotherapy: report on two cases.
Few cases of myopathy have been reported in patients treated with ezetimibe as monotherapy or in association with a statin. We report on two cases of elevation of CKP that occurred upon monotherapy with ezetimibe, which were reversible after discontinuation of the drug. In both cases, patients previously experienced intolerance with other lipid-lowering agents. The pathogenesis of muscle toxicity associated with ezetimibe is not known yet. An interaction with statin or a toxicity mechanism common to several lipid-lowering drugs have been suggested. A potential role of induction of glucuronidation by numerous associated drugs can also be involved Although association of ezetimibe with myopathy seems to be uncommon, special attention should be given to patients treated with ezetimibe who had a previous intolerance to other lipid-lowering drugs and who received several drugs.
Meas
T
T
Internal Medicine A and B Department, AP-HP, Hôpital Lariboisière, 2, rue Ambroise-Paré 75010 Paris, France. taly.meas@lrb.aphp.fr
Cimadevilla
C
C
Timsit
J
J
Mouly
S
S
Guillausseau
P J
PJ
D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D001384:Azetidines / Q000627:therapeutic use*; D003402:Creatine Kinase / Q000097:blood* / Q000187:drug effects; D003404:Creatinine / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy* / Q000201:enzymology; D000069438:Ezetimibe; D005260:Female; D011345:Fenofibrate / Q000627:therapeutic use; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood; D008297:Male; D008875:Middle Aged
D000924:Anticholesteremic Agents; D001384:Azetidines; D003402:Creatine Kinase; D003404:Creatinine; D000069438:Ezetimibe; D011345:Fenofibrate; D006442:Glycated Hemoglobin